Medindia on MSN
Novel CtDNA Blood Test to Track and Treat Prostate Cancer
India, March 23 -- Advances in cancer research are improving how doctors diagnose and monitor diseases. One emerging tool is ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...
The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...
GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant ...
PHILADELPHIA, PA – The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate ...
The global statistics are terrifying. Prostate cancer is the fourth most common cancer in all populations, the second most common cancer among men worldwide, and ranks first in Europe, where a third ...
Hosted on MSN
Early detection cuts prostate cancer death risk by up to 50% : Why PSA testing is a must for all men
Prostate cancer is still among the most prevalent cancers of men globally, but timely detection is everything. Over recent years, medical professionals have been emphasizing the key role of a simple ...
An informational website and a mobile testing van in Philadelphia are making it easier to learn about cancer and get tested. Hall of Fame running back Emmitt Smith will be hosting a series of short ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic ...
Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial “Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results